What is AM-Pharma?
Founded in 2001 and headquartered in Utrecht, the Netherlands, AM-Pharma is a late-stage clinical development and pharmaceutical manufacturing company. Its primary focus is on developing treatments for sepsis-associated acute kidney injury (AKI), a severe condition with significant unmet medical needs. The company's trajectory, marked by consistent capital raises across various funding rounds from Series A through Series F, indicates a robust development pipeline and a strong commitment to bringing innovative therapies to market. This sustained backing from prominent investors highlights confidence in AM-Pharma's scientific approach and commercial potential within the competitive biopharmaceutical landscape.
How much funding has AM-Pharma raised?
AM-Pharma has raised a total of $325.2M across 6 funding rounds:
Series A
$781K
Series C
$3M
Series D
$34.5M
Series E
$14.4M
Private Equity
$87.5M
Series F
$185M
Series A (2001): $781K with participation from Biopartners Capital
Series C (2007): $3.1M led by Inventages and Forbion Capital
Series D (2011): $34.5M supported by BB Biotech Ventures, Inventages, Kurma Partners, Idinvest Partners, Forbion, and Ysios Capital Partners
Series E (2014): $14.4M featuring Kuma Biofund, IDInvest Partners, Gilde Healthcare, AbbVie, Ysios Capital, and BB Biotech Ventures
Private Equity (2015): $87.5M backed by Pfizer
Series F (2020): $185M with participation from Cowen Healthcare Investments, Kurma Partners, European Investment Bank, Ysios Capital, Andera Partners, ID Invest Partners, Gilde Healthcare, Life Sciences Partners, and BB Pureos Bioventures
Key Investors in AM-Pharma
AbbVie
AbbVie Inc. is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines and health solutions that address some of the worlds most complex medical challenges. Headquartered in North Chicago, Illinois, the company operates internationally and focuses on advancing treatments that improve patient outcomes and overall quality of life.
Ysios Capital
Ysios Capital is a leading life sciences venture capital firm that invests in highly innovative biotechnology companies worldwide. The firm provides biotech ventures with the necessary resources to develop novel therapies aimed at addressing significant unmet medical needs.
Gilde Healthcare
Gilde Healthcare is a specialized healthcare investment firm managing over €1.4 billion across three fund strategies: Venture & Growth in Healthcare, Private Equity in Healthcare, and Private Equity in Climate Solutions. The firm focuses on investing in businesses that enable better care at lower costs and address planetary challenges through energy transition, biodiversity, and waste management.
What's next for AM-Pharma?
With substantial backing and a clear focus on a critical unmet medical need, AM-Pharma is poised for significant advancements in its clinical development and manufacturing capabilities. The company's strategic investments suggest a phase of accelerated growth, likely involving the progression of its lead candidates through late-stage clinical trials and potential commercialization efforts. Future capital injections or strategic partnerships may be anticipated as AM-Pharma aims to scale its operations and expand its therapeutic reach, further solidifying its position in the global pharmaceutical market.
See full AM-Pharma company page
